Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Oaknin

Showing results (31-40 of 173) with videos related to

Pageof 18
Sort By:
Journal of Gynecologic Oncology|September 19, 2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATccMunetaka Takekuma, Shin Nishio, Satoshi Yamaguchi, et al.
Gynecologic Oncology|May 1, 2015
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerScott McMeekin, Don Dizon, James Barter, et al.
ESMO Open|April 10, 2019
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancerVictor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, et al.
Trends in Cancer|March 25, 2025
Molecular and clinical insights into early-onset endometrial cancerZimeng Wu, Zhe Hu, Qinlan Li, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]Ana Oaknin, Rosa Guarch, Pilar Barretina, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2014
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumorsRamon Salazar, Serafin Morales, Marta Gil-Martín, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2013
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancerAntonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, et al.
Scientific Reports|February 25, 2021
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumorsAndres Poveda, Ana Oaknin, Ignacio Romero, et al.
Cancers|July 15, 2026
Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA StatusDavid García-Illescas, Víctor Navarro, Lorena Fariñas-Madrid, et al.
Journal of Minimally Invasive Gynecology|June 17, 2018
Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive TechniquesAntonio Gil-Moreno, Melchor Carbonell-Socias, Sabina Salicrú, et al.
Pageof 18

Showing results (31-40 of 173) with videos related to

Sort By:
Pageof 18
Journal of Gynecologic Oncology|September 19, 2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATccMunetaka Takekuma, Shin Nishio, Satoshi Yamaguchi, et al.
Gynecologic Oncology|May 1, 2015
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerScott McMeekin, Don Dizon, James Barter, et al.
ESMO Open|April 10, 2019
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancerVictor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, et al.
Trends in Cancer|March 25, 2025
Molecular and clinical insights into early-onset endometrial cancerZimeng Wu, Zhe Hu, Qinlan Li, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]Ana Oaknin, Rosa Guarch, Pilar Barretina, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2014
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumorsRamon Salazar, Serafin Morales, Marta Gil-Martín, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2013
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancerAntonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, et al.
Scientific Reports|February 25, 2021
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumorsAndres Poveda, Ana Oaknin, Ignacio Romero, et al.
Cancers|July 15, 2026
Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA StatusDavid García-Illescas, Víctor Navarro, Lorena Fariñas-Madrid, et al.
Journal of Minimally Invasive Gynecology|June 17, 2018
Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive TechniquesAntonio Gil-Moreno, Melchor Carbonell-Socias, Sabina Salicrú, et al.
Pageof 18